ARCTURUS THERAPEUTICS HOLDINGS INC. Earnings Per Share (Basic)
ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) reported Earnings Per Share (Basic) of -$0.84 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-06
- ARCTURUS THERAPEUTICS HOLDINGS INC. earnings per share, basic for the quarter ending 2026-06-30 was -$0.84.
- ARCTURUS THERAPEUTICS HOLDINGS INC. earnings per share, basic for the quarter ending 2026-03-31 was -$0.95.
- ARCTURUS THERAPEUTICS HOLDINGS INC. earnings per share, basic for the quarter ending 2025-12-31 was -$1.03.
- ARCTURUS THERAPEUTICS HOLDINGS INC. earnings per share, basic for the quarter ending 2025-09-30 was -$0.49.
- ARCTURUS THERAPEUTICS HOLDINGS INC. earnings per share, basic for fiscal 2025 was -$2.40.
- ARCTURUS THERAPEUTICS HOLDINGS INC. earnings per share, basic for fiscal 2024 was -$3.00.
- ARCTURUS THERAPEUTICS HOLDINGS INC. earnings per share, basic for fiscal 2023 was -$1.12, a 420.00% decline from fiscal 2022.
- ARCTURUS THERAPEUTICS HOLDINGS INC. earnings per share, basic for fiscal 2022 was $0.35.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.84 10-Q · filed 2026-08-06 | -$1.79 10-Q · filed 2026-08-06 | -$2.82 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$3.33 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2026-03-31 | -$0.95 10-Q · filed 2026-05-07 | -$1.98 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$2.49 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$2.84 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-12-31 | -$1.03 derived: net income ÷ weighted average shares · filed 2026-03-03 | -$1.54 derived: net income ÷ weighted average shares · filed 2026-03-03 | -$1.88 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$2.40 10-K · filed 2026-03-03 |
| 2025-09-30 | -$0.49 10-Q · filed 2025-11-12 | -$0.83 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.35 10-Q · filed 2025-11-12 | -$2.46 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-06-30 | -$0.34 10-Q · filed 2026-08-06 | -$0.86 10-Q · filed 2026-08-06 | -$1.96 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$2.22 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-03-31 | -$0.52 10-Q · filed 2026-05-07 | -$1.63 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.88 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$2.52 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2024-12-31 | -$1.11 derived: net income ÷ weighted average shares · filed 2026-03-03 | -$1.36 derived: net income ÷ weighted average shares · filed 2026-03-03 | -$2.00 derived: net income ÷ weighted average shares · filed 2026-03-03 | -$3.00 10-K · filed 2026-03-03 |
| 2024-09-30 | -$0.26 10-Q · filed 2025-11-12 | -$0.89 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$1.89 10-Q · filed 2025-11-12 | -$2.33 derived: net income ÷ weighted average shares · filed 2026-03-03 |
| 2024-06-30 | -$0.64 10-Q · filed 2025-08-11 | -$1.64 10-Q · filed 2025-08-11 | -$2.07 derived: net income ÷ weighted average shares · filed 2026-03-03 | -$2.68 derived: net income ÷ weighted average shares · filed 2026-03-03 |
| 2024-03-31 | -$1.00 10-Q · filed 2025-05-12 | -$1.43 derived: net income ÷ weighted average shares · filed 2026-03-03 | -$2.05 derived: net income ÷ weighted average shares · filed 2026-03-03 | -$4.02 derived: net income ÷ weighted average shares · filed 2026-03-03 |
| 2023-12-31 | -$0.44 derived: net income ÷ weighted average shares · filed 2026-03-03 | -$1.05 derived: net income ÷ weighted average shares · filed 2026-03-03 | -$3.02 derived: net income ÷ weighted average shares · filed 2026-03-03 | -$1.12 10-K · filed 2026-03-03 |
| 2023-09-30 | -$0.61 10-Q · filed 2024-11-07 | -$2.59 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$0.68 10-Q · filed 2024-11-07 | $2.14 derived: net income ÷ weighted average shares · filed 2025-03-06 |
| 2023-06-30 | -$1.98 10-Q · filed 2024-08-05 | -$0.07 10-Q · filed 2024-08-05 | $2.18 derived: net income ÷ weighted average shares · filed 2025-03-06 | $2.02 derived: net income ÷ weighted average shares · filed 2025-03-06 |
| 2023-03-31 | $1.91 10-Q · filed 2024-05-08 | $2.54 derived: net income ÷ weighted average shares · filed 2025-03-06 | $3.01 derived: net income ÷ weighted average shares · filed 2025-03-06 | $3.36 derived: net income ÷ weighted average shares · filed 2025-03-06 |
| 2022-12-31 | $1.11 derived: net income ÷ weighted average shares · filed 2025-03-06 | $1.55 derived: net income ÷ weighted average shares · filed 2025-03-06 | $1.72 derived: net income ÷ weighted average shares · filed 2025-03-06 | $0.35 10-K · filed 2025-03-06 |
| 2022-09-30 | -$1.33 10-Q · filed 2023-11-14 | -$2148.87 derived: net income ÷ weighted average shares · filed 2023-11-14 | -$4.09 10-Q · filed 2023-11-14 | -$22.19 derived: net income ÷ weighted average shares · filed 2024-03-14 |
| 2022-06-30 | -$0.82 10-Q · filed 2023-08-07 | -$2.75 10-Q · filed 2023-08-07 | -$12.65 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$12.55 derived: net income ÷ weighted average shares · filed 2024-03-14 |
| 2022-03-31 | -$1.94 10-Q · filed 2023-05-09 | -$6.81 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$8.19 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$10.04 derived: net income ÷ weighted average shares · filed 2024-03-14 |
| 2021-12-31 | -$1.47 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$3.52 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$5.59 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$7.74 10-K · filed 2024-03-14 |
| 2021-09-30 | -$2.05 10-Q · filed 2022-11-09 | -$4.13 derived: net income ÷ weighted average shares · filed 2022-11-09 | -$6.27 10-Q · filed 2022-11-09 | |
| 2021-06-30 | -$2.07 10-Q · filed 2022-08-09 | -$4.22 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |